Mitera Biosciences is focused on advancing investigational therapeutics that leverage the biology of the human innate immune system, particularly targeting transplant rejection and autoimmune diseases. The company aims to develop safer and more effective alternatives to traditional immunosuppressive therapies, which often rely on calcineurin inhibitors (CNI) like cyclosporine and tacrolimus. While these current standard treatments can be effective in the short term, they come with significant risks and long-term adverse effects, including toxicity that can lead to neurologic and kidney injuries. Mitera recognizes the urgent need for improved therapies, especially given that over 50% of kidney transplant patients experience CNI intolerance, which can result in serious complications such as chronic antibody-mediated rejection.

To address these challenges, Mitera Biosciences is concentrating on the biology of Regulatory T cells (Tregs), which play a crucial role in maintaining immune system balance. The company is developing a novel therapeutic drug candidate that aims to enhance the number of circulating Tregs, thereby potentially mitigating the harmful effects of an overactive immune response. This innovative approach is based on proprietary intellectual property licensed from Cedars Sinai Medical Center and seeks to activate a unique biological pathway within the innate immune system. If successful, this therapeutic candidate could provide a non-toxic alternative to existing immunosuppressants, offering hope for patients in need of better treatment options for organ transplant maintenance and autoimmune disorders.

United States

Mitera is a maternal-fetal medicine (MFM) telehealth company. We help inform and educate our patients about their pregnancy-related risks and options through obstetrical screenings and at-home genetic testing kits, empowering them along their family-forming journey.

Mitera Biosciences

Company Details